Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi-GI3: Ivonescimab + FOLFOX vs Bevacizumab + FOLFOX in First-line Metastatic Colorectal Cancer
jRCT2031250629Phase 3Recruiting
- Sponsor
- Summit Therapeutics
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of ivonescimab in metastatic colon cancer (mCRC) (2 arms), sponsored by Summit Therapeutics. Primary endpoint: Progression-free survival. Started Apr 2026; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on jRCT2031250629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250629.